Generic-to-generic lamotrigine switches in people with epilepsy: the randomised controlled EQUIGEN trial

@article{Privitera2016GenerictogenericLS,
  title={Generic-to-generic lamotrigine switches in people with epilepsy: the randomised controlled EQUIGEN trial},
  author={Michael D. Privitera and Timothy E. Welty and Barry E. Gidal and Francisco Jos{\'e} Gonz{\'a}lez D{\'i}az and Michel J. Berg},
  journal={The Lancet Neurology},
  year={2016},
  volume={15},
  pages={365-372}
}
BACKGROUND Patients and clinicians share concerns that generic drug substitution might lead to loss of efficacy or emergence of adverse events. In this trial, we assessed US Food and Drug Administration (FDA) bioequivalence standards by studying the effects of switching between two disparate generic immediate-release lamotrigine products in patients with epilepsy. METHODS The Equivalence among Generic Antiepileptic Drugs (EQUIGEN) chronic-dose study was a randomised, double-blind, crossover… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 34 CITATIONS

Community pharmacists' understanding and perceptions of FDA therapeutic equivalence standards.

  • Research in social & administrative pharmacy : RSAP
  • 2019
VIEW 1 EXCERPT
CITES BACKGROUND